MD Sermorelin research: GHRH analogs and relatives

GHRH analog mechanism

Sermorelin stimulates growth hormone release as a GHRH analog: it activates the receptor normally reached by growth hormone-releasing hormone. Its target cells in the anterior pituitary, called somatotrophs, make and release GH. Receptor activation raises cAMP and engages protein kinase A, CREB-dependent GH gene transcription and calcium-driven release of stored GH. Walker’s account of the mechanism emphasizes the continuing influence of somatostatin and IGF-1 feedback.

Sermorelin’s 29-amino-acid sequence retains activity from native GHRH. The GHRH-analog development review describes the subsequent work on modified relatives. That history explains why a paragraph about “GHRH” may concern a compound with a different persistence or target application.

The immune system adds another kind of recognition. That coexistence gives me two meanings for “recognized by the body”: successful receptor activity and antibody formation.

Antibody findings across formulations

The Chen study in GH-deficient children reported GHRH antibodies in nearly all participants, without a relationship to growth. In Lanes and Carrillo’s longer follow-up, antibodies in several responders likewise appeared compatible with continued growth. By contrast, the PEG-conjugated GHRH study reported no antibodies to GHRH.

Those studies differ in preparation, population and exposure. I resist awarding a formulation a safety advantage from that comparison alone. A head-to-head investigation of antibody function and clinical response would be much more persuasive than a tally of positive assays.

A separate continuous-infusion study in six children found that GH output declined by 3 to 6 months, with complete suppression in one child. Antibodies, somatostatin changes and receptor desensitization were among the possibilities investigated. The study leaves the explanation open; antibody detection elsewhere cannot resolve it.

Adult trial notebook

Vittone, 1997. In 11 healthy men aged 64-76, 6 weeks of GHRH(1-29) increased nocturnal GH release and measured upper-body strength. IGF-1 did not rise significantly, and body-composition measurements remained unchanged. It is a small experiment with a mixed set of outcomes.

Khorram, 1997. The 16-week study in 19 men and women used [Nle27]GHRH(1-29)-NH2. Nocturnal GH and IGF-1 increased in both sexes; men gained an average of 1.26 kg lean mass, and both sexes showed increased skin thickness. The sex-specific findings deserve to stay attached to the result.

Vitiello, 2006. Five months in 89 healthy older adults doubled 24-hour GH secretion, raised IGF-1 by ~40%, reduced body fat by ~5% and improved processing-speed scores by 5-7%. Slow-wave sleep architecture did not significantly change.

Baker, 2012. The 20-week trial in 152 adults aged 55-87 used tesamorelin. IGF-1 rose 117%, body fat fell 7.4%, lean mass increased 3.7% and executive function improved (p=0.005). This is the larger adult trial, and the compound distinction is essential.

Friedman, 2013. MR spectroscopy in 30 adults from the Baker cohort found higher GABA in three brain regions, higher NAAG in dorsolateral frontal cortex and lower myo-inositol in posterior cingulate. This was a substudy of the same cohort. I value the extra look at brain chemistry while resisting the temptation to count it as an independent replication.

Growth hormone analog research

The family resemblance has practical limits. Tesamorelin and later GHRH ligands were developed with modifications that alter their behavior. The historical pharmacokinetic summary reports an 11-12 minute terminal half-life for sermorelin; a shared receptor does not erase differences in exposure.

A ghrelin mimetic acts through the ghrelin/GHS receptor, a different route from sermorelin’s GHRH receptor. GHRP-2 and GHRP-6 appear alongside ipamorelin in discussions of complementary GH-releasing pathways. The broader GHRH biology review situates GHRH signaling within this endocrine setting.

Questions about somatorelin, or capromorelin in humans, require the original compound and trial to be identified. This source collection supplies no dedicated trial for either term. I won’t substitute a sermorelin result for a missing capromorelin result simply because both appear in a conversation about growth hormone.

MR-409 in mice

The MR-409 Alzheimer’s-model report concerns mice: the analog reduced amyloid-β deposition, astrogliosis, neuron loss and Tau phosphorylation while elevating BDNF. Earlier [[D-Ala2]-GHRH work in aged rodents](https://pubmed.ncbi.nlm.nih.gov/10737685/) reported attenuation of spatial-memory deficits.

The analog-development review also describes regenerative applications beyond the pituitary. Animal and cell findings give the field questions to test. They earn my curiosity without supplying adult sermorelin outcomes.